Recently, early phase clinical trials have begun to look at the utility of BMI-1 inhibitors in advanced solid tumors (clinicaltrials.gov #NCT02404480), gliomas (clinicaltrials.gov #NCT03605550), and for relapsed/refractory AML (clinicaltrials.gov #NCT03761069). This evidence concerns the gene BMI1 and central nervous system cancer.